Cannara Biotech Inc.
LOVE.V
TSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.10% | 27.58% | 28.40% | 25.18% | 30.37% |
| Total Other Revenue | 33.99% | 106.79% | 621.65% | 2,355.56% | 55.91% |
| Total Revenue | 25.23% | 27.90% | 28.85% | 25.48% | 30.71% |
| Cost of Revenue | 12.20% | 12.69% | 14.54% | 25.13% | 54.14% |
| Gross Profit | 48.09% | 54.46% | 52.60% | 25.98% | 3.17% |
| SG&A Expenses | 18.98% | 14.91% | 17.24% | 20.39% | 43.09% |
| Depreciation & Amortization | 21.85% | 11.60% | 25.03% | 24.52% | 15.01% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.63% | 12.49% | 14.50% | 23.06% | 49.31% |
| Operating Income | 134.20% | 177.73% | 143.43% | 38.67% | -39.80% |
| Income Before Tax | 212.77% | 299.69% | 214.98% | 111.84% | -41.96% |
| Income Tax Expenses | 520.31% | 351.28% | -- | -- | -- |
| Earnings from Continuing Operations | 75.55% | 100.52% | 182.88% | 109.88% | -28.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.55% | 100.52% | 182.88% | 109.88% | -28.60% |
| EBIT | 134.20% | 177.73% | 143.43% | 38.67% | -39.80% |
| EBITDA | 79.91% | 99.95% | 86.56% | 29.37% | -25.02% |
| EPS Basic | 72.80% | 98.46% | 188.97% | 115.23% | -27.19% |
| Normalized Basic EPS | 457.93% | 772.73% | 468.71% | 86.20% | -67.49% |
| EPS Diluted | 75.69% | 118.24% | 223.33% | 136.64% | -28.12% |
| Normalized Diluted EPS | 466.43% | 793.68% | 463.70% | 84.41% | -68.47% |
| Average Basic Shares Outstanding | 1.96% | 0.88% | -0.24% | -0.81% | -0.50% |
| Average Diluted Shares Outstanding | 2.68% | 1.58% | 0.76% | 0.49% | 0.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |